257 related articles for article (PubMed ID: 10716879)
1. In vitro characterization of five humanized OKT3 effector function variant antibodies.
Xu D; Alegre ML; Varga SS; Rothermel AL; Collins AM; Pulito VL; Hanna LS; Dolan KP; Parren PW; Bluestone JA; Jolliffe LK; Zivin RA
Cell Immunol; 2000 Feb; 200(1):16-26. PubMed ID: 10716879
[TBL] [Abstract][Full Text] [Related]
2. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
Cole MS; Anasetti C; Tso JY
J Immunol; 1997 Oct; 159(7):3613-21. PubMed ID: 9317161
[TBL] [Abstract][Full Text] [Related]
3. Humanization of the murine anti-human CD3 monoclonal antibody OKT3.
Adair JR; Athwal DS; Bodmer MW; Bright SM; Collins AM; Pulito VL; Rao PE; Reedman R; Rothermel AL; Xu D
Hum Antibodies Hybridomas; 1994; 5(1-2):41-7. PubMed ID: 7858182
[TBL] [Abstract][Full Text] [Related]
4. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.
Alegre ML; Tso JY; Sattar HA; Smith J; Desalle F; Cole M; Bluestone JA
J Immunol; 1995 Aug; 155(3):1544-55. PubMed ID: 7636216
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
Le Gall F; Reusch U; Moldenhauer G; Little M; Kipriyanov SM
J Immunol Methods; 2004 Feb; 285(1):111-27. PubMed ID: 14871540
[TBL] [Abstract][Full Text] [Related]
6. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
[TBL] [Abstract][Full Text] [Related]
7. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
Alegre ML; Peterson LJ; Xu D; Sattar HA; Jeyarajah DR; Kowalkowski K; Thistlethwaite JR; Zivin RA; Jolliffe L; Bluestone JA
Transplantation; 1994 Jun; 57(11):1537-43. PubMed ID: 8009586
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
Woodle ES; Xu D; Zivin RA; Auger J; Charette J; O'Laughlin R; Peace D; Jollife LK; Haverty T; Bluestone JA; Thistlethwaite JR
Transplantation; 1999 Sep; 68(5):608-16. PubMed ID: 10507477
[TBL] [Abstract][Full Text] [Related]
9. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression.
Woodle ES; Thistlethwaite JR; Jolliffe LK; Zivin RA; Collins A; Adair JR; Bodmer M; Athwal D; Alegre ML; Bluestone JA
J Immunol; 1992 May; 148(9):2756-63. PubMed ID: 1533410
[TBL] [Abstract][Full Text] [Related]
10. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro.
Cole MS; Stellrecht KE; Shi JD; Homola M; Hsu DH; Anasetti C; Vasquez M; Tso JY
Transplantation; 1999 Aug; 68(4):563-71. PubMed ID: 10480417
[TBL] [Abstract][Full Text] [Related]
11. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.
Silva HM; Vieira PM; Costa PL; Pimentel BM; Moro AM; Kalil J; Maranhão AQ; Coelho V; Brigido MM
Immunol Lett; 2009 Aug; 125(2):129-36. PubMed ID: 19573559
[TBL] [Abstract][Full Text] [Related]
12. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions.
Li B; Wang H; Dai J; Ji J; Qian W; Zhang D; Hou S; Guo Y
Immunology; 2005 Dec; 116(4):487-98. PubMed ID: 16313362
[TBL] [Abstract][Full Text] [Related]
13. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.
Bolt S; Routledge E; Lloyd I; Chatenoud L; Pope H; Gorman SD; Clark M; Waldmann H
Eur J Immunol; 1993 Feb; 23(2):403-11. PubMed ID: 8436176
[TBL] [Abstract][Full Text] [Related]
14. Structured to reduce the mitogenicity of anti-CD3 antibody based on computer-guided molecular design.
Lv M; Li Y; Yu M; Sun Y; Lin Z; Qiao C; Luo Q; Gu X; Huang Y; Feng J; Shen B
Int J Biochem Cell Biol; 2007; 39(6):1142-55. PubMed ID: 17446118
[TBL] [Abstract][Full Text] [Related]
15. Recombinant chimeric OKT3 scFv IgM antibodies mediate immune suppression while reducing T cell activation in vitro.
Choi I; De Ines C; Kürschner T; Cochlovius B; Sörensen V; Olafsen T; Sandlie I; Little M
Eur J Immunol; 2001 Jan; 31(1):94-106. PubMed ID: 11169443
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3.
Bonnefoy-Berard N; Revillard JP
J Heart Lung Transplant; 1996 May; 15(5):435-42. PubMed ID: 8771497
[TBL] [Abstract][Full Text] [Related]
17. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.
Abbs IC; Clark M; Waldmann H; Chatenoud L; Koffman CG; Sacks SH
Ther Immunol; 1994 Dec; 1(6):325-31. PubMed ID: 7584508
[TBL] [Abstract][Full Text] [Related]
18. A humanised mouse model of cytokine release: comparison of CD3-specific antibody fragments.
Malcolm SL; Smith EL; Bourne T; Shaw S
J Immunol Methods; 2012 Oct; 384(1-2):33-42. PubMed ID: 22796190
[TBL] [Abstract][Full Text] [Related]
19. Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation.
Zhu Z; Carter P
J Immunol; 1995 Aug; 155(4):1903-10. PubMed ID: 7636241
[TBL] [Abstract][Full Text] [Related]
20. Prevention of the OKT3 first-dose syndrome by reduced initial dose followed by adjusted doses based on CD3 T-lymphocyte counts in pediatric renal graft recipients.
Piatosa B; Grenda R; Prokurat S
Transplant Proc; 1996 Dec; 28(6):3466-7. PubMed ID: 8962349
[No Abstract] [Full Text] [Related]
[Next] [New Search]
